Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jay Fawver

Psychiatry Angola, IN Medical Doctor

NPI 1164457404 CMS profile 52467

301 E Maumee St, Angola, IN 46703

Open in the dashboard

General payments

$1,420,274

1,574 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jay Fawver of Angola, IN is reported in the CMS Open Payments database as having received $1,420,274 across 1,574 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $305,986 285
2024 General $254,354 232
2023 General $317,190 298
2022 General $251,039 293
2021 General $98,043 134
2020 General $42,732 97
2019 General $150,930 235

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Fawver
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Jay Fawver were reported at $305,986. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Jay Fawver Psychiatry median Middle half National median
2019 $150,930 $184 $59–$605 $163
2020 $42,732 $119 $36–$372 $114
2021 $98,043 $143 $43–$576 $132
2022 $251,039 $153 $50–$590 $149
2023 $317,190 $170 $56–$651 $160
2024 $254,354 $179 $57–$673 $164
2025 $305,986 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $659,406 648 payments
  2. Axsome Therapeutics, Inc. $379,387 281 payments
  3. Alkermes, Inc. $258,023 302 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $56,885 102 payments
  5. Biogen, Inc. $25,932 36 payments
  6. ITI, Inc. $17,339 38 payments
  7. H. Lundbeck A S $12,463 4 payments
  8. Janssen Scientific Affairs, LLC $4,701 12 payments
  9. Sage Therapeutics, Inc. $3,774 3 payments
  10. Lundbeck LLC $291 20 payments
  11. Other $2,073 128 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $839,755 342 payments
  2. Consulting Fee $250,700 93 payments
  3. Travel and Lodging $197,993 453 payments
  4. Honoraria $105,394 32 payments
  5. Food and Beverage $26,328 651 payments
  6. Education $104 3 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $664,045 656 payments
  2. Auvelity $379,387 281 payments
  3. LYBALVI Cns $257,982 301 payments
  4. LYBALVI Cns $257,938 298 payments
  5. LYBALVI Cns $257,928 297 payments
  6. LYBALVI Cns $257,928 297 payments
  7. Trintellix $31,501 52 payments
  8. Zurzuvae $25,909 34 payments
  9. CAPLYTA $17,093 26 payments
  10. BRINTELLIX $12,605 15 payments
  11. Other $27,569 240 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

127

Median for Psychiatry: 574

Drug cost

$11,117

Median for Psychiatry: $27,624

Branded share of claims

18.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 11 $9,355
Trazodone Hcl Generic 21 $528
Gabapentin Generic 38 $500
Lamotrigine Generic 20 $228
Bupropion Xl Bupropion Hcl Brand 12 $207
Duloxetine Hcl Generic 13 $185
Pregabalin Generic 12 $114

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
$131,681 — —
SPRAVATO
$87,797 — —
LYBALVI
$32,623 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,574 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record